Remove Resources Preclinical
article thumbnail

InvisiShield and Gladstone partner to develop intranasal preventatives

Pharmaceutical Technology

Scientists at Gladstone Institutes will be responsible for carrying out preclinical studies to assess the efficacy and safety of the product. Under the partnership terms, InvisiShield will offer technical support, as well as funding to develop the intranasal preventatives.

article thumbnail

HanAll Biopharma and Daewoong sign deal to develop Parkinson’s therapy

Pharmaceutical Technology

HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. They will help to progress ATH-399A towards a Phase I trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734

PharmaShots

IMP1734 showed a high anti-tumor activity and a wide therapeutic window in the preclinical in vivo models Ref: prnewswire | Image: Impact Therapeutics Related News:- IMPACT Therapeutics’ IMP4297 and Temozolomide Receives the US FDA’s Orphan Drug Designation for Small Cell Lung Cancer PharmaShots!

FDA 40
article thumbnail

Intrinsic Medicine enters merger with Phoenix Biotech

Pharmaceutical Technology

The merged business’ cash resources are estimated to offer Intrinsic the capital to progress its lead compound, OM002, and other pipeline assets. These resources will also be used to fund a Phase IIb clinical trial of OM002 in more than 400 subjects with constipation dominant form of irritable bowel syndrome (IBS-C).

article thumbnail

Neurocrine Bio agrees $57m takeover of UK biotech Diurnal

pharmaphorum

The Cardiff-based company’s pipeline also includes an oral testosterone in clinical trials for hypogonadism, as well as a modified-release levothyroxine for hypothyroidism and oligonucleotide-based therapy for Cushing’s disease in preclinical development.

104
104
article thumbnail

Reaction Biology to acquire Vyant Bio subsidiary’s operations in US

Pharmaceutical Technology

This investment in talent, infrastructure and resources is an important step in our roadmap for fully realising Reaction’s potential as a provider of solutions for the discovery and development of new drug candidates.”.

52
article thumbnail

Separating the Hype from the Hyperbole Surrounding FDORA’s Alternatives to Animal Testing under the FD&C Act

The FDA Law Blog

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.” 21 U.S.C. § 355(i)(1)(A).

FDA 64